Inflammatory Disease News and Research

RSS

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with IgG4-Related Disease (IgG4-RD).

8 Mar 2016

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis today announced that the United States Food and Drug Administration approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic.

26 Feb 2016

Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy designation to PKC412 (midostaurin). PKC412 (midostaurin) is an investigational treatment for adults with newly-diagnosed AML who are FLT3 mutation-positive, as detected by an FDA-approved test, and who are eligible to receive standard induction and consolidation chemotherapy.

19 Feb 2016

New research identifies key enzyme linked to age-related increases in cancer and inflammation

For the first time, researchers have shown that an enzyme key to regulating gene expression -- and also an oncogene when mutated -- is critical for the expression of numerous inflammatory compounds that have been implicated in age-related increases in cancer and tissue degeneration, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

4 Feb 2016

BioLineRx's BL-7010 confirmed as Class IIb medical device in European Union

BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received confirmation from the European Notified Body regarding the classification of BL-7010, a novel polymer for the treatment of celiac disease, as a Class IIb medical device in the European Union.

25 Jan 2016

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announced today that the US Food and Drug Administration has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).

17 Jan 2016

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine.

24 Dec 2015

Pelvic pain linked to poor mental health outcomes among women with endometriosis

A new study published in the Journal of Psychosomatic Obstetrics & Gynecology has found that women who suffer from pelvic pain caused by endometriosis may need psychological intervention in order to help improve their mental health and quality of life.

22 Dec 2015

Periodontal disease may increase breast cancer risk

Postmenopausal women with periodontal disease were more likely to develop breast cancer than women who did not have the chronic inflammatory disease. A history of smoking significantly affected the women's risk.

21 Dec 2015

New way of growing fallopian tube cells in culture may boost understanding of female genital diseases

A new way of growing fallopian tube cells in culture is expected to give a boost to our understanding and prevention of female gynecological diseases, such as infertility, inflammatory disease, and ovarian cancer.

12 Dec 2015

Circuit awarded contract to pursue optogenetic therapies for peripheral nervous system indications

Circuit Therapeutics today announced that it has been awarded a 2.7 million dollar contract from the Defense Advanced Research Projects Agency to pursue optogenetic therapies for peripheral nervous system indications. The award, part of DARPA's Electrical Prescriptions (ElectRX) program, will enable Circuit to pursue research and development projects related to its treatment for neuropathic pain.

10 Dec 2015

Medical professionals compare different treatment methods for Neuromyelitis optica

In the course of a study conducted throughout Germany, medical professionals have compared different treatment methods for Neuromyelitis optica, an inflammatory disease of the central nervous system. It turned out that the best results were not achieved with conventional steroid therapy. Under the auspices of the Ruhr-Universität Bochum and the Hannover Medical School, the team published their findings in the journal Annals of Neurology.

30 Nov 2015

Can-Fite BioPharma reports financial results, provides updates on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the nine months ended September 30, 2015 and updates on its drug development programs.

27 Nov 2015

Medical professionals compare different treatment options for Neuromyelitis optica

26 Nov 2015

Ultrasound can help identify patients at increased risk of future stroke

Ultrasound, a non-invasive technique commonly used to study the presence of atherosclerosis disease in blood vessels, can be used to identify patients at increased risk of future stroke who could benefit from surgery. Since surgical treatment to prevent stroke is only considered beneficial to some, ultrasound can prove useful in preventing unnecessary surgical intervention, new research at Umeå University in Sweden shows.

25 Nov 2015

ProMetic, ProThera form strategic partnership to develop and commercialize Inter-alpha Inhibitor Proteins

ProMetic Life Sciences Inc. announced today that it has entered into a strategic partnership with ProThera Biologics Inc. for the development and commercialization of human plasma-derived Inter-alpha Inhibitor Proteins.

19 Nov 2015

TTUHSC nephrologists to help find new treatment for lupus nephritis

Nephrologists at Texas Tech University Health Science Center El Paso have been invited to participate in a national consortium that's investigating the key causes of lupus nephritis -- an autoimmune disease that can cause kidney failure.

17 Nov 2015

No progression in joint damage in 84% of psoriatic arthritis patients

Novartis announced today new results for Cosentyx® (secukinumab) showing no further progression in joint damage in 84% of patients with psoriatic arthritis (PsA). In addition, Cosentyx maintained a treatment response in joint and skin disease, physical function and quality of life in patients over two years of treatment. These results from the extension phase of the FUTURE 1 study were presented at the 2015 Annual Meeting of the American College of Rheumatology (ACR) in San Francisco, United States.

9 Nov 2015

Novartis’ Cosentyx® show no progression in spinal damage in 80% of ankylosing spondylitis patients

Novartis announced today late-breaking two year results for Cosentyx® (secukinumab) showing up to 80% of patients with ankylosing spondylitis (AS) had no radiographic progression in the spine on x-ray assessment. This is the first time that data on structural spinal progression in AS have been presented for an interleukin-17A (IL-17A) inhibitor.